Sphera Funds Management LTD. raised its stake in shares of Cellectis SA (NASDAQ:CLLS) by 27.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 447,970 shares of the biotechnology company’s stock after acquiring an additional 96,096 shares during the period. Cellectis makes up 1.5% of Sphera Funds Management LTD.’s holdings, making the stock its 12th biggest holding. Sphera Funds Management LTD. owned approximately 1.08% of Cellectis worth $12,642,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds also recently made changes to their positions in CLLS. FMR LLC increased its position in shares of Cellectis by 18.0% during the second quarter. FMR LLC now owns 4,240,010 shares of the biotechnology company’s stock valued at $119,949,000 after acquiring an additional 647,164 shares during the last quarter. BlackRock Inc. increased its position in shares of Cellectis by 259.7% during the second quarter. BlackRock Inc. now owns 443,713 shares of the biotechnology company’s stock valued at $12,552,000 after acquiring an additional 320,340 shares during the last quarter. Nexthera Capital LP increased its position in shares of Cellectis by 64.7% during the second quarter. Nexthera Capital LP now owns 548,212 shares of the biotechnology company’s stock valued at $15,509,000 after acquiring an additional 215,458 shares during the last quarter. Laurion Capital Management LP acquired a new stake in shares of Cellectis during the second quarter valued at about $5,658,000. Finally, ARK Investment Management LLC increased its position in shares of Cellectis by 178.8% during the second quarter. ARK Investment Management LLC now owns 244,263 shares of the biotechnology company’s stock valued at $6,910,000 after acquiring an additional 156,666 shares during the last quarter. Institutional investors and hedge funds own 27.68% of the company’s stock.
Shares of NASDAQ CLLS traded up $0.22 during midday trading on Friday, hitting $20.85. The company’s stock had a trading volume of 444 shares, compared to its average volume of 151,113. Cellectis SA has a 1 year low of $20.15 and a 1 year high of $38.85. The firm has a market cap of $897.01 million, a price-to-earnings ratio of -7.47 and a beta of 1.71.
A number of brokerages have weighed in on CLLS. Zacks Investment Research upgraded shares of Cellectis from a “hold” rating to a “buy” rating and set a $25.00 price target for the company in a research report on Friday, November 16th. ValuEngine raised shares of Cellectis from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. BidaskClub lowered shares of Cellectis from a “sell” rating to a “strong sell” rating in a research note on Wednesday, November 21st. Finally, Oppenheimer set a $44.00 price objective on shares of Cellectis and gave the company a “buy” rating in a research note on Sunday, November 25th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $48.00.
TRADEMARK VIOLATION WARNING: “Cellectis SA (CLLS) Holdings Raised by Sphera Funds Management LTD.” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/12/07/cellectis-sa-clls-holdings-raised-by-sphera-funds-management-ltd.html.
Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).
Featured Article: What are the benefits of a balanced fund?
Want to see what other hedge funds are holding CLLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellectis SA (NASDAQ:CLLS).
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.